目的：比较胰岛素泵输注赖脯胰岛素（优泌乐）与重组人胰岛素（优泌林R）治疗初诊2型糖尿病的疗效及安全性。方法：选择45例本院初诊2型糖尿病患者行胰岛素泵强化治疗，并按随机数字表法分为优泌乐组和优泌林R组，比较两组各点血糖、血糖达标时间、血糖达标时胰岛素用量及低血糖发生率。结果：优泌乐组的血糖达标时间较优泌林R组短，胰岛素用量也较少，餐后血糖值更低，差异均有统计学意义（P<0.05）；但两组餐前血糖及睡前血糖比较差异无统计学意义（P>0.05）。结论：用胰岛素泵输注优泌乐和优泌林R均能安全、有效的控制初诊2型糖尿病高血糖状态，但优泌乐组血糖达标时间更短，餐后血糖控制更佳，所需胰岛素量更少。%Objective:To compare the efficacy and safety of insulin Lispro and Humulin R via continuous subcutaneous insulin infusion pump on hyperglycemia in newly-diagnosed 2 diabetes. Method:45 patients accepted a 2-week course of intensive CsII were selected. They were divided into group A(n=25)and group B(n=20)according to random number table method. The group A was treated with insulin Lispro,the group B was treated with Humulin R. The therapeutic effects were measured after therapy. Result:The time for good glycemia control was shorter in the group A than that in the group B(P<0.05);the mean of three postprandial blood glucose were significantly lower in the group A than that in the group B,with lower total insulin dosage,the differences were statistically significant(P<0.05);but no differences in blood glucose between the two groups were observed in bedtime and before three meals(P>0.05). Conclusion:Insulin Lispro via continuous subcutaneous insulin infusion pump is as efficacious and safe as Humulin R in controlling hyperglycemia in newly-diagnosed type 2 diabetes,but insulin Lispro provides a more effective and faster control of postprandial hyperglycemia with less insulin used.
展开▼
